Slide 1: Annual General Meeting Monday 25th November 2024
For personal use only Annual General Meeting Monday 25th November 2024
Slide 2: We create, deliver & invest in highly disruptive product innovation
For personal use only We create, deliver & invest in highly disruptive product innovation across global markets that improve People’s Lives
Slide 3: Hydrix Limited – Board of Directors
Hydrix Limited – Board of Directors For personal use only Mr Gavin Coote Mr Paul Wright Mr Paul Lewis Ms Julie King Ms Alyn Tai Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Corporate Counsel Gavin has extensive executive Paul spent 18 years as CEO of Paul s
Slide 4: Emerging as an innovative medtech & cardiovascular health technology business
Emerging as an innovative medtech & cardiovascular For personal use only health technology business Tracking progress of our Buy, Build, Invest strategy 01 02 03 04 05 06 Acquire Hydrix Establish Hydrix Establish Hydrix Build Medical Group Revenue Group Services Ventures Medical Portfolio Growth Pro
Slide 5: International expansion strategy is succeeding
International expansion strategy For personal use only is succeeding 1 Expertise that outweighs distance Revenues International 2 US/EU-based BizDev team 'plugged-into' local markets Australia 72% 53% 57% 3 Global reputation for quality and innovation 26% 4 Point of difference in cardiovascular tech
Slide 6: Driving the business to profit
Driving the business to profit For personal use only Recent quarters revenue growth on significantly lower operating costs bring the Group closer to a profit ($M’s) Hydrix Services made a 6% profit Expenses $3.8 on $2.9m revenues in 1QFY25 $3.2 Trend will include quarterly variations • Significant i
Slide 7: Key objectives next twelve months
Key objectives next twelve months For personal use only 1 Continue to improve Lives globally delivering technology innovation 2 Grow Services 6% profit in 1QF25 to more than 10% from higher revenues and lower fixed cost base 3 Build Medical’s annual recurring subscription revenues by converting sale
Slide 8: For more information, please visit www.hydrix.com
For personal use only For more information, please visit: www.hydrix.com
Slide 9: Recap FY24 business highlights
HYDRIX Services HYDRIX Ventures Recap FY24 • Revenues $10.6m (-19%), 51% • Net Asset value decreased by business highlights For personal use only medtech, 42% cardiac $1.7m to $3.3m due to Avertix Medical (AVRT) Series C • 72% revenues from international down-round fund raising (up 4x v. $FY21) • $4
Slide 10: We create the innovation in breakthrough technologies
We create the innovation For personal use only Market focus in breakthrough • Outsourced product development services - from concept to market technologies • Highly specialised and highly regulated new product development • Safety critical systems e.g., Class III active implantable cardiac technolog
Slide 11: LUDO system testimonial from The Texas Heart Institute
"The LUDO system has proven an incredible asset for The Texas Heart Institute, providing us with everything essential for the success of For personal use only our LVAD projects” Yaxin Wang, PhD Associate Investigator Director, Innovative Device and Engineering Applications, The Texas Heart Institute
Slide 12: We deliver the innovation in breakthrough technologies
We deliver the innovation For personal use only Market focus in breakthrough • Cardiovascular disease afflicts 14% of the population; the leading cause of death technologies • Cardiac diagnostic & remote patient monitoring (RPM) using AI/ML devices • Mix of revenue models: recurring subscriptions, d
Slide 13: Remote diagnostic & monitoring technologies to manage heart disease
Remote diagnostic & monitoring For personal use only technologies to manage heart disease Deals completed Distribution Product features Addressable market / Rev model AUS, NZ, SING A universal, alert-based • 65k+ patients to monitor platform for cardiac remote • Revenue type: annual subscription mon
Slide 14: We invest in the innovation in breakthrough technologies
We invest in the innovation For personal use only Medical Venture Capital Investment Strategy in breakthrough • Selectively invest in clients developing breakthrough technologies technologies • Early stage, minority investment, <5-years to commercialisation • Target >5x cash multiple liquidity event
Slide 15: Corporate snapshot and capitalisation table
Corporate snapshot Capitalisation table For personal use only Major Shareholders Shares (m) % Capital Structure (as of 20 November 2024) John W. King & related entities 27.3 10.7 Ticker HYD Paul Lewis & related entities 16.6 6.5 Share Price $0.01 Pusen Medical Technology Australia Pty Ltd 12.0 4.7 S
Slide 16: Disclaimer
Disclaimer For personal use only The material in this presentation has been prepared by Hydrix Limited (“Hydrix”) ACN 060 369 048 and is general background information about Hydrix's activities current at the date of this presentation. The information is given in summary form and does not purport to
Slide 17: For more information, please visit www.hydrix.com
For personal use only For more information, please visit: www.hydrix.com